BR112019005581A2 - método de alívio dos sintomas da síndrome pré-menstrual - Google Patents
método de alívio dos sintomas da síndrome pré-menstrualInfo
- Publication number
- BR112019005581A2 BR112019005581A2 BR112019005581A BR112019005581A BR112019005581A2 BR 112019005581 A2 BR112019005581 A2 BR 112019005581A2 BR 112019005581 A BR112019005581 A BR 112019005581A BR 112019005581 A BR112019005581 A BR 112019005581A BR 112019005581 A2 BR112019005581 A2 BR 112019005581A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxaloacetate
- swelling
- premenstrual syndrome
- symptom relief
- relief method
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
a presente invenção refere-se a métodos de tratamento dos sintomas da pms e do pmdd, incluindo dor muscular, inchaço, cólicas, acne, seios sensíveis, inchaço, fadiga, dificuldade de concentração, diminuição do controle de impulsos, irritabilidade, ansiedade, tensão, raiva, depressão, insônia e/ou oscilações rápidas de humor (alterações de humor). o método compreende a administração de uma composição farmacêutica compreendendo oxaloacetato, sais de oxaloacetato, ácido oxaloacético e/ou enol-oxaloacetato anidro.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662398319P | 2016-09-22 | 2016-09-22 | |
PCT/US2017/052718 WO2018057737A1 (en) | 2016-09-22 | 2017-09-21 | Method to alleviate the symptoms of pms |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019005581A2 true BR112019005581A2 (pt) | 2019-06-11 |
Family
ID=59997500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019005581A BR112019005581A2 (pt) | 2016-09-22 | 2017-09-21 | método de alívio dos sintomas da síndrome pré-menstrual |
Country Status (9)
Country | Link |
---|---|
US (3) | US11071722B2 (pt) |
EP (1) | EP3515428B1 (pt) |
JP (1) | JP7291079B2 (pt) |
KR (1) | KR102542842B1 (pt) |
AU (2) | AU2017330348B2 (pt) |
BR (1) | BR112019005581A2 (pt) |
CA (1) | CA3037235A1 (pt) |
ES (1) | ES2950096T3 (pt) |
WO (1) | WO2018057737A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3037235A1 (en) * | 2016-09-22 | 2018-03-29 | Alan B. Cash | Method to alleviate the symptoms of pms |
WO2021137257A1 (en) | 2020-01-01 | 2021-07-08 | Celagenex Research (India) Pvt. Ltd. | Synergistic nutritional compositions for enhancing atp efficiency |
EP4277615A1 (en) | 2021-01-14 | 2023-11-22 | Alan B Cash | Treatment of pathological fatigue with oxaloacetate |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
US4670248A (en) * | 1985-08-15 | 1987-06-02 | International Minerals & Chemical Corp. | Olivine bolus |
US5155105A (en) | 1986-09-15 | 1992-10-13 | Bristol-Myers Squibb Company | Pharmaceutical methods for relief of dysmenorrhea and/or premenstrual syndrome and process |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
US4943435A (en) | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
US4839174A (en) | 1987-10-05 | 1989-06-13 | Pharmetrix Corporation | Novel transdermal nicotine patch |
US4908213A (en) | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
CA2075517C (en) | 1992-04-01 | 1997-03-11 | John Wick | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5474527A (en) | 1993-03-29 | 1995-12-12 | Bettinger; David S. | Positive displacement transdermal system |
WO1994023716A1 (en) | 1993-04-16 | 1994-10-27 | Tufts University School Of Medicine | Method for treatment of menopausal and premenstrual symptoms |
US6057439A (en) | 1994-08-04 | 2000-05-02 | Pherin Corporation | Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety |
US5612061A (en) | 1994-10-14 | 1997-03-18 | Rabkin; Simon W. | Composition and method for the treatment of premenstrual syndrome |
JP2874583B2 (ja) | 1995-02-10 | 1999-03-24 | 日本電気株式会社 | 半導体装置の入力保護回路 |
US5569459A (en) | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5707630A (en) | 1996-01-04 | 1998-01-13 | Sabina International, Ltd. | Herbal compound for relief of PMS through menopausal symptoms |
WO1997038701A1 (en) * | 1996-04-12 | 1997-10-23 | Neotech Medical Innovations In | Composition and method for the treatment of premenstrual syndrome |
US5654011A (en) | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
US6987101B1 (en) | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
CA2306875C (en) | 1997-10-24 | 2011-01-04 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
US6322823B1 (en) | 1999-05-27 | 2001-11-27 | Lenore C. Mannella | PMS defense: an aromatherapy compound for the relief of symptoms of premenstrual syndrome |
US6174542B1 (en) | 1999-07-01 | 2001-01-16 | Pms Mood Food, Inc. | Dietary supplements and food products for treating symptoms of PMS |
US7473426B2 (en) | 2001-02-27 | 2009-01-06 | Yun Seok Choe | Method for selectively inhibiting reuptake of serotonin and norepinephrine using yeast extract |
WO2003049744A1 (en) | 2001-12-05 | 2003-06-19 | Barr Laboratories, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US20030119913A1 (en) * | 2001-12-20 | 2003-06-26 | Ohia Sunny E. | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof |
US7897147B2 (en) | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
EP1824470B1 (en) | 2004-12-17 | 2014-08-06 | Alan B. Cash | Method for extending lifespan and delaying the onset of age-related disease |
WO2006105019A1 (en) | 2005-03-25 | 2006-10-05 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure disorders |
US8124598B2 (en) | 2006-09-14 | 2012-02-28 | Sharon Sageman | 7-keto DHEA for psychiatric use |
US8399432B2 (en) | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US9050306B2 (en) * | 2010-06-22 | 2015-06-09 | Alan B. Cash | Activation of AMP-protein activated kinase by oxaloacetate compounds |
US20150210964A1 (en) * | 2014-01-24 | 2015-07-30 | The Procter & Gamble Company | Consumer Product Compositions |
EP3056199A1 (en) * | 2015-02-12 | 2016-08-17 | Alan B Cash | Modification of the ph and other physical properties of oxaloacetic acid to allow for enhanced stability |
CA3037235A1 (en) * | 2016-09-22 | 2018-03-29 | Alan B. Cash | Method to alleviate the symptoms of pms |
-
2017
- 2017-09-21 CA CA3037235A patent/CA3037235A1/en active Pending
- 2017-09-21 JP JP2019537043A patent/JP7291079B2/ja active Active
- 2017-09-21 KR KR1020197011465A patent/KR102542842B1/ko active IP Right Grant
- 2017-09-21 US US16/335,652 patent/US11071722B2/en active Active
- 2017-09-21 AU AU2017330348A patent/AU2017330348B2/en active Active
- 2017-09-21 ES ES17777759T patent/ES2950096T3/es active Active
- 2017-09-21 BR BR112019005581A patent/BR112019005581A2/pt active Search and Examination
- 2017-09-21 EP EP17777759.6A patent/EP3515428B1/en active Active
- 2017-09-21 WO PCT/US2017/052718 patent/WO2018057737A1/en unknown
-
2021
- 2021-06-22 US US17/354,866 patent/US11865092B2/en active Active
-
2023
- 2023-11-29 US US18/523,772 patent/US20240115529A1/en active Pending
- 2023-12-04 AU AU2023274237A patent/AU2023274237A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017330348A1 (en) | 2019-04-11 |
US20210308083A1 (en) | 2021-10-07 |
EP3515428B1 (en) | 2023-06-07 |
JP7291079B2 (ja) | 2023-06-14 |
AU2017330348B2 (en) | 2023-09-07 |
KR20190084248A (ko) | 2019-07-16 |
EP3515428C0 (en) | 2023-06-07 |
CA3037235A1 (en) | 2018-03-29 |
US20240115529A1 (en) | 2024-04-11 |
US11865092B2 (en) | 2024-01-09 |
US20190321315A1 (en) | 2019-10-24 |
ES2950096T3 (es) | 2023-10-05 |
KR102542842B1 (ko) | 2023-06-14 |
EP3515428A1 (en) | 2019-07-31 |
WO2018057737A1 (en) | 2018-03-29 |
JP2019529559A (ja) | 2019-10-17 |
AU2023274237A1 (en) | 2023-12-21 |
US11071722B2 (en) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
BR112013023803A2 (pt) | dispositivo para inervação magnética extracorpórea | |
BR112019005581A2 (pt) | método de alívio dos sintomas da síndrome pré-menstrual | |
BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
BR112013031032A2 (pt) | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos | |
ECSP19043725A (es) | Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares | |
EA201491221A1 (ru) | Новые молекулы, ингибирующие jnk, для лечения различных болезней | |
CY1122273T1 (el) | Διαδερμικες συνθεσεις ιβουπροφαινης και μεθοδοι χρησης αυτων | |
BR112012008282A2 (pt) | anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos | |
BR112015023725A2 (pt) | composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme | |
BR112015001847A2 (pt) | composições e tratamento para doenças e distúrbios nos olhos | |
BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
BR112012018256A8 (pt) | método de tratamento de doença de parkinson | |
BR112018013522A2 (pt) | compostos inibidores de metaloenzima | |
BR112015023020A2 (pt) | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas | |
EA202091396A1 (ru) | Композиции и способы лечения метаболических состояний | |
EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
BR112014030813A2 (pt) | tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson | |
BR112015024926A2 (pt) | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe | |
BR112015011213A2 (pt) | Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição. | |
CY1121436T1 (el) | Δοσολογια για τους αναστολεις των kinασων janus (jak) | |
EA201690997A1 (ru) | Композиция для применения в лечении стойкого кашля | |
BR112016014081A2 (pt) | Tratamento fotodinâmico de pulso da acne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |